Title
Category
Credits
Event date
Cost
NCCN Guidelines® Insights - Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
  • Ovarian Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Archived NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.
Recorded Presentation from the NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas
  • Glioma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.
NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024
  • Management of Immunotherapy-Related Toxicities
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Acute Myelogenous Leukemia
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy. The preferred treatment option for BPDCN is the CD123 targeted therapy tagraxofusp ersz. Tagraxofusp-ersz can be associated with potentially life-threatening capillary leak syndrome, and it is crucial to be aware of management strategies if utilizing this agent.
Evaluation and Treatment of Primary Central Nervous System Lymphoma
  • CNS Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Neuroradiologic evaluation, an important part of diagnosis and evaluation of the effectiveness of subsequent therapy, can be confounded by steroids administration used to alleviate symptoms of primary central nervous system lymphomas (PCNSL). These confounding, non-diagnostic results can delay therapies for PCNSL, which commonly consist of methotrexate-based induction and consolidation treatments. Even with therapy, more than half the cases will relapse or be refractory to therapy.
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens. Bispecific antibodies represent a novel treatment option for heavily pretreated FL, including disease relapse following CAR T-cell therapy.
Management of TP53 Mutated Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients. Recent data have shown that BTK inhibitor-based regimens result in favorable outcomes in patients with previously untreated classical MCL with TP53 mutation. Chimeric antigen receptor (CAR) T-cell therapy also results in favorable response rates in previously treated classical MCL with TP53 mutation.

Pages